Three months ago, MDxHealth was selling a comeback story. Second-quarter revenue had jumped 14% sequentially to $27.2 million, the largest quarter-over-quarter gain in the company's history, and management described 2026 as a two-to-three-quarter setback rather than a lasting problem. That story has since broken down. The company has already told investors to expect third-quarter revenue of roughly $22.7 million and has suspended its full-year forecast of $110 million to $115 million. When it reports after the close on November 12, the question is no longer whether the quarter beats. It is whether management can explain what went wrong and show it has a credible plan.

The published consensus has not caught up. Analysts are still listed at $28.5 million in revenue and a loss of $0.07 per share, figures that imply modest 3.9% year-over-year growth and a loss less than half the size of last year's $0.16. Those numbers appear stale. Management's own estimate sits about $5.8 million below the Street, and $22.7 million would be a drop of roughly 17% both from the second quarter and from the $27.4 million reported a year ago. Because the pre-announcement removes most of the revenue suspense, the reported top line matters less than everything around it. Given the shortfall, the earnings consensus also looks optimistic unless costs fell sharply.

The first thing to look for is the source of the shortfall. Last quarter, management said the recovery depended on tissue-based prostate test volumes picking up in the back half of the year. Those volumes were still flat to down year over year in the second quarter, while competitors were growing in the mid-teens. Management also flagged third-quarter seasonality as a possible wild card. If the miss comes from a temporary factor, such as timing, collections or seasonal softness, while test volumes held up, the rebound narrative is damaged but not finished. If tissue volumes themselves fell, it would suggest the strong second quarter was a one-off bounce after the transition of Resolve customers, rather than evidence of lasting demand.

Profitability and the balance sheet are the second test. Adjusted EBITDA swung to a $2.3 million loss in the second quarter. Gross margin also slipped to 65.7% from 68.6% a year earlier because of a less favorable mix of tissue and liquid tests. Management had already softened its goal of a 10% EBITDA margin exiting 2026 to simply returning to positive EBITDA by year end. A quarter with about $4.5 million less revenue makes even that reduced goal hard to reach, so investors need to hear whether it still stands. Cash is the other key figure. After the $20 million registered direct offering in August, pro forma cash was $39.2 million. That cushion now has to cover operating losses, debt and the remaining Exact Sciences earn-out obligations. A clear view of cash burn and any plans to cut costs may matter more than the revenue figure itself.

The market has already passed a harsh judgment. Shares have fallen about 74% since the last report, compared with a 3% decline in the S&P 500. At $0.16, the stock trades just above its post-earnings low of $0.15 and far below its 200-day moving average of $1.50. Sentiment remains heavily bearish at 73%, though somewhat less so than the 82% reading before last quarter's report. That suggests some investors believe the worst news is already reflected in the price.

With expectations this low, the report can still matter if it brings clarity. Positive developments would include stable or rising tissue volumes, progress on the PROMPT and PROTECT clinical studies, and a firm timeline for reinstating guidance. Without them, the earlier claim that 2026 was a temporary setback becomes difficult to defend.